News Releases
May 17, 2022
Merus to Present at the H.C. Wainwright Global Investment Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief
May 09, 2022
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Company to host investor call on Sunday, June 5 at 6:00 p.m. CT - Clinical data update of petosemtamab (Peto) and MCLA-129 planned for second half of 2022
Apr 27, 2022
Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the
Apr 25, 2022
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced
Apr 08, 2022
Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022
– MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung cancer (NSCLC) cells – MCLA-129 significantly inhibits growth of a patient-derived EGFR exon20 insertion (exon20ins) tumor in a preclinical
Apr 06, 2022
Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 06, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg , M.D., President, Chief
Mar 08, 2022
Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting
- The poster details the mechanism of action of MCLA-129 in vitro and effectiveness in vivo in an EGFR exon20 insertion (ex20ins) non-small cell lung cancer (NSCLC) model UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V.
Feb 28, 2022
Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
As of February 2022 , more than 100 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy Clinical data updates planned for lead program Zeno in 1H22 and for petosemtamab (“MCLA-158”) and MCLA-129 in 2H22 Based on the Company’s current
Feb 03, 2022
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief
Jan 25, 2022
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the